P822: A PHASE 1 SINGLE ASCENDING DOSE STUDY OF CAN106, A LONG-ACTING ANTI-C5 COMPLEMENT MONOCLONAL ANTIBODY IN CLINICAL DEVELOPMENT FOR PNH AND OTHER COMPLEMENT-MEDIATED DISEASES
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000846172.64321.0a |
| _version_ | 1797281727369969664 |
|---|---|
| author | C. M. KHOO X. SONG Q. WU G. F. COX |
| author_facet | C. M. KHOO X. SONG Q. WU G. F. COX |
| author_sort | C. M. KHOO |
| collection | DOAJ |
| first_indexed | 2024-03-07T17:01:37Z |
| format | Article |
| id | doaj.art-13013a22484244c2b55a29f8c750adc9 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T17:01:37Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-13013a22484244c2b55a29f8c750adc92024-03-03T03:19:43ZengWileyHemaSphere2572-92412022-06-01671671710.1097/01.HS9.0000846172.64321.0a202206003-00716P822: A PHASE 1 SINGLE ASCENDING DOSE STUDY OF CAN106, A LONG-ACTING ANTI-C5 COMPLEMENT MONOCLONAL ANTIBODY IN CLINICAL DEVELOPMENT FOR PNH AND OTHER COMPLEMENT-MEDIATED DISEASESC. M. KHOO0X. SONG1Q. WU2G. F. COX31 Department of Medicine, National University Hospital, Singapore, Singapore2 Clinical Development and Medical Affair, CANbridge Pharmaceuticals Inc., Shanghai, China2 Clinical Development and Medical Affair, CANbridge Pharmaceuticals Inc., Shanghai, China3 Clinical Development and Medical Affair, CANbridge Pharmaceuticals Inc., Cambridge, MA, United States of Americahttp://journals.lww.com/10.1097/01.HS9.0000846172.64321.0a |
| spellingShingle | C. M. KHOO X. SONG Q. WU G. F. COX P822: A PHASE 1 SINGLE ASCENDING DOSE STUDY OF CAN106, A LONG-ACTING ANTI-C5 COMPLEMENT MONOCLONAL ANTIBODY IN CLINICAL DEVELOPMENT FOR PNH AND OTHER COMPLEMENT-MEDIATED DISEASES HemaSphere |
| title | P822: A PHASE 1 SINGLE ASCENDING DOSE STUDY OF CAN106, A LONG-ACTING ANTI-C5 COMPLEMENT MONOCLONAL ANTIBODY IN CLINICAL DEVELOPMENT FOR PNH AND OTHER COMPLEMENT-MEDIATED DISEASES |
| title_full | P822: A PHASE 1 SINGLE ASCENDING DOSE STUDY OF CAN106, A LONG-ACTING ANTI-C5 COMPLEMENT MONOCLONAL ANTIBODY IN CLINICAL DEVELOPMENT FOR PNH AND OTHER COMPLEMENT-MEDIATED DISEASES |
| title_fullStr | P822: A PHASE 1 SINGLE ASCENDING DOSE STUDY OF CAN106, A LONG-ACTING ANTI-C5 COMPLEMENT MONOCLONAL ANTIBODY IN CLINICAL DEVELOPMENT FOR PNH AND OTHER COMPLEMENT-MEDIATED DISEASES |
| title_full_unstemmed | P822: A PHASE 1 SINGLE ASCENDING DOSE STUDY OF CAN106, A LONG-ACTING ANTI-C5 COMPLEMENT MONOCLONAL ANTIBODY IN CLINICAL DEVELOPMENT FOR PNH AND OTHER COMPLEMENT-MEDIATED DISEASES |
| title_short | P822: A PHASE 1 SINGLE ASCENDING DOSE STUDY OF CAN106, A LONG-ACTING ANTI-C5 COMPLEMENT MONOCLONAL ANTIBODY IN CLINICAL DEVELOPMENT FOR PNH AND OTHER COMPLEMENT-MEDIATED DISEASES |
| title_sort | p822 a phase 1 single ascending dose study of can106 a long acting anti c5 complement monoclonal antibody in clinical development for pnh and other complement mediated diseases |
| url | http://journals.lww.com/10.1097/01.HS9.0000846172.64321.0a |
| work_keys_str_mv | AT cmkhoo p822aphase1singleascendingdosestudyofcan106alongactingantic5complementmonoclonalantibodyinclinicaldevelopmentforpnhandothercomplementmediateddiseases AT xsong p822aphase1singleascendingdosestudyofcan106alongactingantic5complementmonoclonalantibodyinclinicaldevelopmentforpnhandothercomplementmediateddiseases AT qwu p822aphase1singleascendingdosestudyofcan106alongactingantic5complementmonoclonalantibodyinclinicaldevelopmentforpnhandothercomplementmediateddiseases AT gfcox p822aphase1singleascendingdosestudyofcan106alongactingantic5complementmonoclonalantibodyinclinicaldevelopmentforpnhandothercomplementmediateddiseases |